There has been research conducted on the antitumor effect of apatinib on human osteosarcoma.[30] The results showed that osteosarcoma patients with high levels of VEGFR2 have a poor prognosis and deactivation of the VEGFR2/STAT3/BCL2 signaling pathway leads to apatinib-induced growth inhibition of osteosarcoma. The gene discussed is BCL2; the disease is osteosarcoma.